DaVita Inc. (DVA)
- Previous Close
132.77 - Open
131.70 - Bid 131.17 x 1000
- Ask 131.48 x 1200
- Day's Range
130.96 - 132.40 - 52 Week Range
71.51 - 141.54 - Volume
27,607 - Avg. Volume
812,469 - Market Cap (intraday)
11.486B - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
17.73 - EPS (TTM)
7.42 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
132.00
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
www.davita.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DVA
Performance Overview: DVA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVA
Valuation Measures
Market Cap
11.59B
Enterprise Value
22.32B
Trailing P/E
17.89
Forward P/E
14.45
PEG Ratio (5yr expected)
1.19
Price/Sales (ttm)
1.02
Price/Book (mrq)
10.98
Enterprise Value/Revenue
1.84
Enterprise Value/EBITDA
9.62
Financial Highlights
Profitability and Income Statement
Profit Margin
5.70%
Return on Assets (ttm)
5.92%
Return on Equity (ttm)
38.53%
Revenue (ttm)
12.14B
Net Income Avi to Common (ttm)
691.53M
Diluted EPS (ttm)
7.42
Balance Sheet and Cash Flow
Total Cash (mrq)
391.67M
Total Debt/Equity (mrq)
405.21%
Levered Free Cash Flow (ttm)
1.2B
Research Analysis: DVA
Company Insights: DVA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: DVA
DVA: Raising target price to $141.00
DAVITA INC has an Investment Rating of HOLD; a target price of $141.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetDVA: Lowering target price to $136.00
DAVITA INC has an Investment Rating of HOLD; a target price of $136.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetDVA: Lowering target price to $141.00
DAVITA INC has an Investment Rating of HOLD; a target price of $141.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetDVA: What does Argus have to say about DVA?
DAVITA INC has an Investment Rating of HOLD; a target price of $142.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice Target